Edith Namakula
ID: UNCST-2022-R006923
|
Antibiotic prescription patterns among inpatients at Mulago National Referral Hospital, Uganda. Incidence, UCG compliance and associated factors
REFNo: HS5646ES
To determine the incidence of antibiotic prescription among inpatients at Mulago National Referral Hospital, Uganda.
|
Uganda |
2025-04-11 14:26:00 |
2028-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Lucy Aciro
ID: UNCST-2023-R007829
|
Income Diversification and Climate Change Adaptation among smallholder farmer in Northern Uganda
REFNo: A567ES
1. To determine the alternative livelihood strategies among smallholder wood charcoal producers
2. To analyze the effect of income diversification options on food security and living standards of the smallholder wood charcoal producers
3. To assess the climate change adaptation strategies adopted by smallholder wood charcoal producers
4. To determine the willingness of the farmers to adopt different strategies or productions process that enhances sustainability
|
Uganda |
2025-04-11 14:24:32 |
2028-04-11 |
Agricultural Sciences |
Non-Clinical Trial |
Degree Award |
|
Eleanor Namusoke Magongo
ID: UNCST-2021-R013199
|
Uganda Paediatric Antiretroviral Therapy (UP-ART) -THRIVE Sub-study on diagnosis, Prevention and Treatment of Advanced HIV disease in Children and Adolescents living with HIV in Uganda
REFNo: HS5592ES
Primary Objective:
1.To assess the cascade (receipt of all components of care with in one month of being eligible for screening), of care among children and adolescents living with HIV (CALHIV) with advanced HIV disease (AHD), dissecting all steps included in the Ugandan national guidelines (including screening for AHD and opportunistic infections (OI), treatment, optimization of care and prophylaxis).
Secondary objectives:
2.Describe the number and proportion of CALHIV who were eligible for AHD screening per calendar year starting in 2023, among all those in follow-up in UP ART that year
3.Describe the prevalence and incidence of AHD and its characteristics at the time of AHD diagnosis.
(i)Prevalence is based on proportion screened for AHD who met the definition of AHD at initial screening
(ii)Incidence will be estimated in two groups:
a.among those screened and not diagnosed with AHD at initial screening who meet the definition of AHD within 12 months of initial screening.
b.among those eligible for screening but were not screened for AHD, who met the definition of AHD within 12 months of becoming eligible for screening
4.Assess the clinical progression and outcomes of children and adolescents with AHD diagnosis, including mortality, morbidity (new and recurrent WHO 3 and 4 events), retention in HIV care, treatment interruption, and growth changes by 12 months after AHD diagnosis.
5.Strengthen data quality and completeness of AHD related data captured in electronic medical records through dedicated training, data monitoring plans and regular feedback to clinic staff.
|
Uganda |
2025-04-11 14:20:45 |
2028-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Grace Ahimbisibwe Miriam
ID: UNCST-2021-R012129
|
Establishing Surveillance for Serious Neonatal Infections in sub-Saharan Africa (SNIP-Africa) Version 2.0 dated 15 Aug 2024
REFNo: HS5614ES
General Objective
To establish capacity and methods to conduct surveillance of neonatal BSI, pathogen and antimicrobial susceptibility profiles, AMR colonisation prevalence (patient and hospital environment) and antibiotic prescribing trends among hospitalised neonates (≤28 days) in sSA neonatal units.
Specific Objectives
i. To set up a surveillance network and define methods to support continuous epidemiological evaluation of neonates with suspected sepsis in participating sSA neonatal units.
ii. To create a streamlined, translatable data capture approach for use across a range of healthcare facilities.
iii. To determine the personnel and physical resources required for ongoing surveillance in different settings.
iv. To develop a real time data dashboard driving quality improvement through surveillance at the level of participating sites.
v. To describe AMR burden and patterns and identify trends in resistant bacterial invasive and carriage isolates in participating units and participants.
vi. To pilot assessment of colonization pressure and the relationship between invasive blood culture isolates, faecal carriage, the hospital environment and antimicrobial usage.
vii. To develop tools to detect and monitor outbreaks within participating neonatal units.
|
Uganda |
2025-04-11 14:17:57 |
2028-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Edgar Mulogo Mugema
ID: UNCST-2023-R008170
|
HIV-Associated Viral Acute Respiratory Tract Illness (HAVARTI): The burden and severity of vaccine-preventable respiratory infection in people living with HIV in rural Uganda.
REFNo: HS5676ES
Primary Objective
The overarching goal of this study is to define the incidence and relative frequency of, and severity of illness from, influenza and two other vaccine-preventable viral respiratory infections, respiratory syncytial virus (RSV) and SARS-CoV-2, among people living with HIV (PLWH) in rural Uganda.
Specific Aims
1. Determine the incidence of ARI in a cohort of individuals living with HIV in rural Uganda and the proportion and incidence of those ARI episodes caused by vaccine-preventable viral respiratory infections (influenza, RSV, and SARS-CoV-2). We will enroll adolescents and adults infected with HIV who receive care at the Antiretroviral Therapy (ART) clinic at Bugoye Health Centre (BHC), a rural peripheral health facility in western Uganda. Participants will self-collect a mid-turbinate nasal swab at the onset of every episode of ARI during the study follow-up period. Samples will be tested for RSV, influenza, and SARS-CoV-2 within 48 hours of collection using a molecular assay.
2. Estimate the morbidity and mortality from influenza, RSV, and SARS-CoV-2 in this same population of PLWH. Study staff will conduct home visits 14 days after the onset of each episode of ARI to assess outcomes. Specifically, they will record any antibiotic or other treatment taken and its source (e.g., purchased at drug shop or prescribed by a healthcare provider); missed days of work (e.g., in the field for subsistence farmers); care-seeking including outpatient visits and inpatient admissions; and vital status.
3. Explore risk factors for severe disease from influenza, RSV, and SARS-CoV-2 among PLWH. As an exploratory aim, we will collect information on demographics, household and socioeconomic factors, cooking methods, past medical history including presence of underlying lung disease, smoking status, and history of pneumonia or tuberculosis, nadir and last CD4 count, most recent HIV viral load (VL) and VL at diagnosis, and ART history.
|
Uganda |
2025-04-11 14:15:22 |
2028-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|